stents

Future second-generation stents, today.

Original title:&nbsp;First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold A Multi-Imaging Modality Study.&nbsp;Reference:&nbsp;John Ormiston et al. Circ Cardiovasc Interv. 2012;5:620-632. The first bioabsorbable stents eluting everolimus showed a 6-month delayed recoil resulting in late lumen loss of 0.44 mm, (intermediate between a metal stent<a href="https://solaci.org/en/2012/11/05/future-second-generation-stents-today/" title="Read more" >...</a>

Drug-Eluting Stents: device without polymers overcomes limitations of first generations stents

The NEXT randomized trial showed the superiority of a polymer-free amphilimus-eluting stent compared to paclitaxel-eluting stents with permanent polymers The NEXT clinical trial (International Randomized Comparison Between DES Limus Carbostent and Taxus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions), is a multicenter randomized trial (n=296) comparing coronary amphilimus eluting stent Cre8 (CID,<a href="https://solaci.org/en/2012/10/01/drug-eluting-stents-device-without-polymers-overcomes-limitations-of-first-generations-stents/" title="Read more" >...</a>

ULTIMATE III: Use of IVUS for Coronary De Novo Lesion Drug Coated Balloon Angioplasty

Percutaneous coronary intervention (PCI) with drug eluting stents (DES) can present limitations, especially in the form of stent thrombosis or instent restenosis (ISR). These findings have furthered the development of drub coated balloons (DCB). The safety and efficacy of DCB have already been shown in the context of ISR and de novo small vessel coronary<a href="https://solaci.org/en/2024/07/12/ultimate-iii-use-of-ivus-for-coronary-de-novo-lesion-drug-coated-balloon-angioplasty/" title="Read more" >...</a>

QFR Analysis of Coronary Lesions with TAVR

While transcatheter aortic valve replacement (TAVR) has shown benefits, significant coronary artery disease affects 50% or more of patients who undergo such procedure. However, it is still unclear which is the best treatment strategy or how to handle this condition. Quantitative flow ratio (QFR) could be a non-invasive option to assess the severity of coronary<a href="https://solaci.org/en/2024/06/29/qfr-analysis-of-coronary-lesions-with-tavr/" title="Read more" >...</a>

La estrategia invasiva en pacientes frágiles es segura

Complex PCI in Octogenarian

The octogenarian population has already reached 137 million and continues to grow. It is estimated to triple by 2050.&nbsp; This increase represents a big challenge, seeing as these patients are often more fragile, present more complex coronary artery disease and multiple comorbidities. This generally requires two or more procedures and more experience both from operators<a href="https://solaci.org/en/2024/06/18/complex-pci-in-octogenarian/" title="Read more" >...</a>

doble antiagregación plaquetaria

Antiplatelet Treatment with Ticagrelor vs. Clopidogrel in Patients with Chronic Coronary Syndrome

Achieving rapid and maximum inhibition of platelet aggregation can reduce complications related to scheduled percutaneous coronary intervention (PCI) in chronic coronary syndromes (CCS). Over the last few decades, the optimal timing for initiating P2Y12 inhibitors and their appropriate dosage have been the subject of numerous studies; however, they have not been clearly established yet. Higher<a href="https://solaci.org/en/2024/06/18/antiplatelet-treatment-with-ticagrelor-vs-clopidogrel-in-patients-with-chronic-coronary-syndrome/" title="Read more" >...</a>

Cilostazol en pacientes diabéticos con revascularización periférica endovascular: Un paso más allá de la mejoría sintomática

Glycemic Control and Coronary Stent Failure

Diabetic patients have twice as high a risk of developing coronary artery disease (CAD). Additionally, CAD increases mortality risk. Patients with a history of percutaneous coronary intervention (PCI) tend to need repeat revascularization, even with second generation stents. To date, there are few studies assessing the role of glycemic control in stent failure, stent thrombosis,<a href="https://solaci.org/en/2024/06/13/glycemic-control-and-coronary-stent-failure/" title="Read more" >...</a>

Resultados alentadores de los balones cubiertos de Biolimus para el tratamiento de vasos pequeños

BIONYX: Onyx vs. Orsiro At 5 Years

Onyx is a zotarolimus-eluting stent (ZES), designed with thin struts and a platinum core that enhances its radiological visibility. This can be beneficial in complex situations with limited visibility, such as in patients who are obese or present severe calcification, two particularly frequent characteristics in diabetic or elderly patients. The BIONYX study was a randomized<a href="https://solaci.org/en/2024/06/05/bionyx-onyx-vs-orsiro-at-5-years/" title="Read more" >...</a>

Novedades en las guías de prevención primaria de la AHA/ACC

LpA: 30-Year Cardiovascular Followup in Primary Prevention Cohorts

For years, treating dyslipidemia mainly focused on reducing LDL cholesterol (LDL-C) with statins, which had shown benefits in reducing atherosclerotic cardiovascular disease (ASCVD). Lipoprotein(a) [Lp(a)] is a form of apoB-containing lipoprotein bound to a hydrophilic, highly glycosylated protein called apolipoprotein(a) [apo(a)]. Circulating levels of Lp(a) are genetically determined, and are hardly affected by eating habits<a href="https://solaci.org/en/2024/04/30/lpa-30-year-cardiovascular-followup-in-primary-prevention-cohorts/" title="Read more" >...</a>

ACC 2024

ACC 2024 | ULTIMATE-DAPT Trial

The international guidelines recommend the use of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor during 12 months in patients receiving percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), to prevent events such as MI and stent thrombosis.&nbsp; This was a multicenter, placebo controlled, double blind study to determine whether ticagrelor alone,<a href="https://solaci.org/en/2024/04/10/acc-2024-ultimate-dapt-trial/" title="Read more" >...</a>

Top